NASDAQ:ATRA - Atara Biotherapeutics, Inc.
$40.06
 $0.63
+1.60%
2:10PM EDT
2019-02-15
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ATRA     avg for
industry  
  avg for
sector  
42 stocks weight:  27. 36   0. 00   0. 00  
42 stocks rank:  3. 41 K 1. 86 K 1. 09 K
# analyst opinions:  6. 00   14. 92   14. 43  
mean recommendation:  2. 10   1. 91   1. 93  

quick ratio:  13. 50   5. 37   1. 81  
current ratio:  13. 81   5. 69   2. 19  

target price low:  23. 00   88. 97   117. 82  
target price avg:  48. 33   115. 19   141. 96  
target price high:  70. 00   143. 40   163. 16  
1-yr high:  51. 45   124. 30   142. 77  
last close:  39. 43   101. 85   127. 84  
50-day avg:  36. 81   98. 27   122. 46  
200-day avg:  39. 22   99. 72   122. 70  
1-yr low:  28. 40   78. 19   100. 16  
volume:  185. 91 K 2. 38 M 4. 64 M
50-day avg volume:  461. 53 K 3. 31 M 4. 94 M
200-day avg volume:  536. 44 K 3. 23 M 4. 28 M

1-day return:  0. 51 % 0. 22 % 0. 48 %
this week return:  2. 44 % 1. 77 % 2. 01 %
12-wk return:  3. 30 % 6. 56 % 3. 33 %
52-wk return:  -16. 62 % -2. 23 % 14. 35 %

enterprise value (EV):  1. 44 B 55. 17 B 104. 51 B
market cap:  1. 80 B 49. 01 B 96. 46 B
EBITDA:  -188. 53 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -7. 63   -91. 79   2. 29  
total debt:  10. 30 M 13. 73 B 16. 57 B
debt/equity:  2. 56   258. 01   110. 73  
net income (common):  -186. 00 M 2. 37 B 3. 58 B

shares outstanding:  45. 65 M 607. 99 M 1. 22 B
shares:  30. 40 M 605. 53 M 1. 15 B
shares short:  6. 43 M 11. 62 M 12. 55 M
shares short prior month:  6. 56 M 11. 95 M 13. 44 M
short ratio:  10. 61   4. 82   3. 10  
short % of float:  23. 16 % 6. 19 % 2. 82 %
total cash/share:  7. 99   12. 02   11. 46  
total cash:  364. 54 M 7. 41 B 7. 37 B
free cash flow:  -119. 92 M 95. 99 M 2. 04 B
operating cash flow:  -147. 29 M 164. 74 M 3. 04 B

book value:  8. 83   14. 43   28. 26  
price/book:  4. 47   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -19. 46 % --- ---
1-yr mean volatility:  0. 03 % 0. 01 % 0. 06 %

1-yr EPS:  -4. 65   3. 03   4. 09  
forward EPS:  -5. 54   4. 33   6. 99  
P/E:  -8. 49   6. 11   26. 91  
forward P/E:  -7. 12   8. 38   10. 48  
PE/G:  1. 17   0. 37   5. 61  
growth:  -7. 28 % 683. 72 % 104. 79 %
earnings high:  -1. 12   1. 27   1. 66  
earnings avg:  -1. 31   1. 01   1. 53  
earnings low:  -1. 46   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -35. 51 % -3. 27 % 3. 81 %
return on equity:  -61. 08 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  1. 53   1. 21   0. 93  
sharpe (1yr):  0. 11   0. 06   0. 98  

held % insiders:  6. 87 % 6. 46 % 3. 21 %
held % institutions:  106. 18 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ATRA
.    + 1.632 =         1.632 :: INITIAL WEIGHT
.  + 344.384 =       346.017 :: inverse volume-to-price addition
.  + 198.674 =        544.69 :: spline projection addition
.  - 141.574 =       403.116 :: poor performance penalty
.    x 0.923 =       372.036 :: one-year gains+dividend factor
.    x 7.428 =      2763.426 :: 13 weeks' performance factor
.    x 1.492 =      4124.382 :: industry recommendation factor
.    x 2.051 =      8459.834 :: symbol recommendation factor
.    x 0.996 =      8429.791 :: return on assets factor
.    x 0.994 =      8378.299 :: return on equity factor
.    x 2.426 =     20327.829 :: current ratio factor
.    x 1.039 =     21125.174 :: quick ratio factor
.    x 1.046 =     22098.292 :: short ratio factor
.    x 2.045 =     45183.375 :: price-to-book factor
.    x 1.005 =     45406.541 :: debt-to-equity factor
.     x 1.06 =     48137.107 :: 5-day avg > 50-day avg
.     x 2.12 =    102059.999 :: P/E weight
.    x 0.962 =     98215.665 :: PE/G factor
.    x 1.395 =    137059.091 :: beta factor
.    x 0.109 =     14906.757 :: sharpe factor
.    x 0.935 =     13944.506 :: target low factor
.    x 1.158 =     16152.833 :: target mean factor
.    x 1.088 =     17575.107 :: target high factor
.    x 1.066 =     18728.259 :: industry 12-weeks return
.    x 0.988 =     18505.612 :: overall "drift" factor
.    x 0.999 =     18490.611 :: largest single-day jump factor
.     x 1.01 =     18675.467 :: mean volatility factor
.    x 1.097 =     20483.362 :: 42-day mean volatility factor
.      x 1.0 =     20484.737 :: factor hist industry gain for week 06
.   cubeRoot =        27.362 :: reduced for readability
.                     27.362 :: FINAL WEIGHT for NASDAQ:ATRA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org